Last Updated : October 3, 2019
Details
FilesGeneric Name:
Pomalidomide
Project Status:
Complete
Therapeutic Area:
Multiple Myeloma
Manufacturer:
Celgene Inc.
Brand Name:
Pomalyst
Project Line:
Reimbursement Review
Project Number:
PC0165-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Strength:
1 mg, 2 mg, 3 mg & 4 mg
Tumour Type:
Myeloma
Indications:
Multiple Myeloma (second-line or beyond)
Funding Request:
Pomalidomide in combination with dexamethasone and bortezomib for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide
Pre Noc Submission:
Yes
Sponsor:
Celgene Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : October 3, 2019